<DOC>
	<DOCNO>NCT02130713</DOCNO>
	<brief_summary>Background - bacterial prostatitis ( BP ) common condition accounting responsible 5-10 % prostatitis case ; chronic bacterial prostatitis ( CBP ) classify type II , less common condition significantly hamper quality life , ( QoL ) physical condition also psychological distress . Commonly patient treat antibiotic alone , particular fluoroquinolones suggest European Urology guideline . This approach , although recommend , may enough . Thus , multimodal approach prolong antibiotic therapy may helpful . Methods - 210 patient affect chronic bacterial prostatitis enrol study . All patient positive Meares-Stamey test symptom duration &gt; 3 month . The purpose study evaluate efficacy long lasting therapy fluoroquinolone association nutraceutical supplement ( prulifloxacin 600 mg 21 day association Serenoa repens 320 mg , Lactobacillus Sporogens 200 mg , Arbutin 100 mg 30 day ) . Patients randomize two group ( A B ) receive respectively antibiotic alone association antibiotic plus supplement .</brief_summary>
	<brief_title>Treatment Chronic Bacterial Prostatitis</brief_title>
	<detailed_description />
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Prulifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>patient affect chronic bacterial prostatitis positivity MearesStamey test symptom duration &gt; 3 month ( dysuria , pelvic pain and/or discomfort ) positivity Chlamydia trachomatis , Ureaplasma urealiticum , Mycoplasma , Neisseria gonorrhoeae , herpes simplex virus ( HSV 1/2 ) human papillomavirus ( HPV ) age le 18 year history neurological disease , urinary stone cancer allergy fluoroquinolones refusal sign inform consent incomplete followup time .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>